Recently, Ministry of Health and Family Welfare launched the State Health Regulatory Excellence Index (SHRESTH), a first-of-its-kind national initiative to benchmark and strengthen state drug regulatory systems through a transparent, data-driven framework
About SHRESTH – State Health Regulatory Excellence Index
- SHRESTH is a virtual gap assessment tool to evaluate, rank, and improve state drug regulatory authorities, ensuring medicine safety, quality, and efficacy.
- Implementing Agency: Central Drugs Standard Control Organization (CDSCO)
- Aim: Ensure safety, quality, and efficacy of medicines through a transparent, data-driven framework.
Objectives & Purpose
- Benchmark performance of State Drug Regulatory Authorities.
- Identify gaps via a virtual gap assessment tool; guide states towards maturity certification.
- Ensure uniform standards across manufacturing & distribution states.
- Promote global trust in Indian medicines; align with Pharmacy of the World vision.
- Build on WHO ML3 status for vaccines, extend similar standards to medicines.
Structure of the Index
- State Categories:
- Manufacturing States – 27 indices across 5 themes:
- Human Resources
- Infrastructure
- Licensing Activities
- Surveillance Activities
- Responsiveness
- Primarily Distribution States/UTs – 23 indices.
- Data Collection:
- States submit predefined metrics to CDSCO by 25th each month.
- Scoring done on the 1st of next month; shared with states/UTs.
Significance
- Drug Safety Assurance: Equal quality standards for all citizens, regardless of geography.
- Federal Cooperation: Centre–state collaboration to regulate India’s vast pharma sector.
- Innovation Push: Encourages tech adoption in regulatory systems.
- Global Competitiveness: Supports India’s export credibility in pharma products.
PWOnlyIAS Extra Edge
About WHO ML3 (Maturity Level 3) status
- WHO ML3 (Maturity Level 3) status, within the context of the WHO Global Benchmarking Tool, signifies that a country’s regulatory system for medicines and other medical products is stable, well-functioning, and integrated.
- It indicates a high level of effectiveness in ensuring the quality, safety, and efficacy of these products.
|
About CDSCO
- CDSCO is India’s National Regulatory Authority (NRA) under the Directorate General of Health Services, Ministry of Health & Family Welfare.
- Headquarters: New Delhi.
- Key Responsibilities of CDSCO
- Safety and Quality: Ensures transparency, accountability, and uniformity in services to maintain the safety, effectiveness, and quality of medical products.
- Approval of New Drugs: Approves new drugs and oversees clinical trials.
- Standards for Drugs: Establishes standards for drugs and controls the quality of imported drugs.
- Collaboration with State Regulators
- Licensing: Along with state authorities, CDSCO grants licenses for critical drugs like blood products, vaccines, IV fluids, and sera.
- Expert Advice: Provides guidance to ensure uniform enforcement of the Drugs and Cosmetics Act across the country.